NGNE News and Press, Neurogene Inc.

2026-04-04 06:40:44 ET Shares of Neurogene Inc. ( NASDAQ:NGNE – Get Free Report ) have been assigned an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated...

2026-03-24 07:41:35 ET More on Neurogene Neurogene: Stock Soars On FDA Designation For Rett Gene Therapy - I'd Remain Cautious Seeking Alpha’s Quant Rating on Neurogene Historical earnings data for Neurogene Financial information for Neurogene ...

100% of participants enrolled in Embolden™ registrational trial and >50% of participants dosed; on track to complete dosing in second quarter of 2026 NGN-401 has been generally well-tolerated in Phase 1/2 trial and Embolden, with no cases of HLH at the 1E15 vg dose; additional i...

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the Stifel 2026 Virtual CNS Forum. Format: Management will part...

2026-02-27 15:32:50 ET Breaking News - Neurogene snags Breakthrough Therapy Designation For Gene Therapy Read the full article on Seeking Alpha For further details see: Neurogene: Stock Soars On FDA Designation For Rett Gene Therapy - I'd Remain Cautious

2026-02-27 09:00:45 ET Neurogene Inc. (NASDAQ: NGNE) shares climbed 30% in after-hours trading Thursday following a significant regulatory milestone. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to NGN-401, the company's investigational gene thera...

Breakthrough Therapy designation granted based on interim NGN-401 Phase 1/2 data demonstrating clinically meaningful, durable and multidomain functional improvements On track to complete dosing in Embolden™ registrational trial of NGN-401 in second quarter of 2026 Plans to ...

Dosed multiple participants in Embolden™ registrational trial in fourth quarter of 2025 Completion of dosing in Embolden expected in second quarter of 2026 Plan to present interim data on pediatric and adolescent/adult cohorts from Phase 1/2 trial in mid-2026 Early ...

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the 44 th Annual J.P. Morgan Healthcare Conference. Format:...

2025-12-16 09:19:08 ET This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F stock portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 11/14/2025. The 13F portfolio value in...